ClinicalTrials.gg

Mood Disorders clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 562 studies for Mood Disorders across more than 10 countries. 106 are recruiting or about to start. 143 of them are mainly about Mood Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 8 narrower conditions too, such as Major Depressive Disorder: 3,862 studies, 745 open.

ClinicalTrials.gov finds 6,878 studies for Mood Disorders. How that becomes 561 here

This page counts the studies the registry files under Mood Disorders, and those it files under no condition that list Mood Disordersthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 6,878Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −3,279Filed under a narrower condition, counted on its own pageBipolar Disorder 1,559 · Depressive Disorder 682 · Depression, Postpartum 541 · Depressive Disorder, Treatment-Resistant 372 · Dysthymic Disorder 56 · Premenstrual Dysphoric Disorder 40 · 1 more
  3. −84List Mood Disorders as a condition, but the registry did not file them under itMost often written as “Schizo Affective Disorder” (55), “Schizo-affective Disorder” (8), and “Affective Disorders, Psychotic” (6). The registry filed them under other conditions only, most often Psychotic Disorders (70) and Schizophrenia (67).
  4. −2,954Match it another way48 name it in the title, 10 in a keyword, and 2,896 by a synonym or other text the search reads.
  5. 561The count on this page6 of them list Mood Disorders in their own words; the registry filed them under no condition.

Status

Completed
363
Recruiting
78
Status unknown
46
Not yet recruiting
21
Terminated
21
Active, not recruiting
18

Phase

Phase 2
77
Phase 1
53
Phase 3
33
Phase 4
30
Early Phase 1
4

Where

United States
269
Canada
48
France
33
Germany
21
United Kingdom
20
Poland
18

Who develops what

Add Mood Disorders to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Eli Lilly and Regeneron Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
duloxetineEarlier only
Evidence
  • NCT01360866 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Duloxetine” · registered May 2011
  • NCT00730691 · Takeda · Phase 3 · comparator · “Duloxetine” · registered Aug 2008
  • NCT00599911 · H. Lundbeck A/S · Phase 2 · comparator · “Duloxetine” · registered Dec 2007
Eli Lilly and Company84% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized00 studies
venlafaxineEarlier only
Evidence
  • NCT01360866 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Venlafaxine XR” · registered May 2011
  • NCT00584974 · Sumitomo Pharma Co., Ltd. · Phase 2 · comparator · “Venlafaxine” · registered Dec 2007
Pfizer35% of its industry studiesUS: off-patent, 28 generics marketed00 studies
quetiapineEarlier only
Evidence
  • NCT01727726 · Otsuka Holdings Co., Ltd. · Phase 3 · comparator · “Seroquel XR” · registered Oct 2012
  • NCT00309699 · Johnson & Johnson · Phase 3 · comparator · “Quetiapine” · registered Mar 2006
AstraZeneca72% of its industry studiesUS: off-patent, 21 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.SPT-300 · Seaport Therapeutics · Phase 2 named, not the main aimNCT07065240 A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — primary endpoint: Change From Baseline to Day 42 in Hamilton Depression Rating Scale-17 (HAM-D-17) Total Score · 360 enrolled
  • May 2027 est.SPT-300 · Seaport Therapeutics · Phase 2 named, not the main aimNCT07161700 An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) — primary endpoint: Safety and tolerability assessments based on Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and validated clinical scales and procedures · 360 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Mood Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SSRIs 2 open · Antipsychotics 1 open · Psychedelics 1 open · Serotonin receptor agonists 1 open · Estrogens 1 open

Coming up

40studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 78 Mood Disorders studies recruiting now, 21 (27%) set no upper age limit and 46 (59%) stop at 75 or younger. 21 (27%) take children under 18. 6 (8%) are for women only and 0 (0%) for men only; 24 (31%) take healthy volunteers.

Recruiting studies that take each age, of 78
AgeWomenMen
1010 (13%)10 (13%)
1863 (81%)59 (76%)
3060 (77%)56 (72%)
4059 (76%)55 (71%)
5059 (76%)56 (72%)
6556 (72%)54 (69%)
7535 (45%)33 (42%)
8528 (36%)26 (33%)

Across all 562 studies, recruiting or not: 64% stop at 75 or younger and 55% at 65; 23% take children; 7% are for women only and 2% for men only; 33% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Mood Disorders studies take

Of 24 phase 2 interventional studies under Mood Disorders, half reached primary completion within 32 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 114 mo8–59 · 14 studies——
Phase 232 mo20–52 · 24 studies——
Interventional, no phase21 mo11–44 · 163 studies—24 mo11–44 · 152 studies
Observational54 mo27–203 · 57 studies—60 mo28–203 · 55 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 562. Browse all 562 → or search them.